Skip to main content

Table 1 Baseline characteristics

From: Quantification of left ventricular mass by echocardiography compared to cardiac magnet resonance imaging in hemodialysis patients

  All patients
(n = 95)
LVH -
(n = 53)
LVH +
(n = 42)
P-value
Age, years 60.0 (50.0–71.0) 59.0 (49.5–68.0) 64 (51.0–72.0) 0.258
Males, n (%) 72 (75.8%) 43 (81.1%) 29 (69.0%) 0.172
Height, m 1.72 (1.66–1.80) 1.72 (1.66–1.81) 1.72 (1,66–1.79) 0.642
Weight, kg 79.0 (68.5–95.0) 86.0 (66.0–102.0) 74.6 (69.0–88.0) 0.066
BMI, kg/m2 26.3 (23.9–31.2) 27.9 (23.8–32.4) 25.4 (23.9–28.5) 0.119
BSA, m2 1.97 (1.79–2.16) 2.02 (1.77–2.22) 1.90 (1.79–2.10) 0.121
Height2.7 4.3 (3.9-4.9) 4.3 (3.9-4.9) 4.3 (3.9-4.8) 0.756
Co-morbidities, n (%)     
Hypertension 86 (90.5) 48 (90.6) 38 (90.5) 1.000
CV events 15 (15.8) 8 (15.1) 7 (16.7) 0.835
CHD 33 (34.7) 19 (35.8) 14 (33.3) 0.798
Heart failure 5 (5.3) 3 (5.7) 2 (4.8) 1.000
Diabetes mellitus 28 (29.5) 13 (24.5) 15 (35.7) 0.235
Medication, n (%)
 Beta-blocker 64 (67.4) 30 (56.6) 34 (81.0) 0.012
 RAS blockade 52 (54.7) 24 (45.3) 28 (66.7) 0.038
 Diuretics 50 (52.6) 24 (45.3) 26 (61.9) 0.107
 CCB 44 (46.3) 21 (39.6) 23 (54.8) 0.142
 Statins 29 (30.5) 16 (30.2) 13 (31.0) 0.936
Dialysis characteristics
 Dialysis duration, months 42.5 (16.8–79.0) 45.0 (17.0–69.0) 42.0 (16.0–85.0) 0.750
 Fistula, n (%) 88 (92.6) 48 (90.6) 40 (95.2) 0.148
  1. Data are presented as median (quartiles) or prevalence (percent). LVH left ventricular hypertrophy; BMI body mass index; BSA body surface area (Mosteller formula); CV cardiovascular; CHD coronary heart disease; RAS renin-angiotensin-system; CCB calcium channel blockers